Urology Coding Alert

Report Prostate Nodules Based on Diagnosis, Procedure and Carrier Requirements

When a urologist palpates a nodule to determine if it is benign, he or she may order transrectal ultrasound (TRUS) (76872), biopsy (55700), the associated ultrasound (76942) and prostate-specific antigen tests (84153, 84154). Only 236.5 and 239.5 tell the payer the test was ordered because the urologist did not know the cause of the lesion. But few insurers will pay for a TRUS on 236.5 or 239.5 only. They want a biopsy also.
 
Note: 76872 Echography, transrectal; 55700 Biopsy, prostate; needle or punch, single or multiple, any approach; 76942 Ultrasonic guidance for needle placement [e.g., biopsy, aspiration, injection, localization device], imaging supervision and interpretation; 84153 Prostate-specific antigen [PSA]; total; 84154 free; 236.5 Neoplasm of uncertain behavior of genitourinary organs; prostate; 239.5 Neoplasms of unspecified nature; other genitourinary organs.
 
Some carriers will pay for all three prostate diagnostic procedures 76872, 55700 and 76942 on the same day with 236.5 or 239.5. Most carriers will deny payment for a TRUS with only 239.5, but they will pay for the biopsy and the ultrasonic guidance. Some will pay for the TRUS with 600.1 (Hyperplasia of prostate; nodular prostate).
 
Choosing the Diagnosis Code

A chart note may say a patient has an "enlarged prostate" that is associated with "BPH" even though benign prostatic hyperplasia (BPH) is a histological diagnosis. "But BPH has been so used in the jargon of urology that instead of saying a patient has an enlarged prostate, many urologists will say the patient has BPH," says Michael A. Ferragamo, MD, clinical assistant professor of urology, State University of New York, Stony Brook. Code 600.0 (Hypertrophy [benign] of prostate) is not for a nodule or a nodular prostate, but BPH can be associated with nodules.
 
"Code 239.5 is probably the most appropriate diagnosis to use in evaluation of an undiagnosed prostatic nodule," Ferragamo explains. "This represents the clinical circumstances of a prostatic nodule requiring a biopsy." However, this is not the best code to use for a TRUS alone, because carriers omit it on medical-necessity lists for 76872.
 
When "prostate nodule" is documented, do not use 600.1 if a suspicion of a malignant process exists, Ferragamo says. If the notes contain a diagnosis of "nodule of the prostate," which the physician evaluated, often with PSA and ultrasonically guided biopsy, use 236.5 or 239.5 based on what the carrier accepts, he recommends.
 
If the physician indicates a nodule of the prostate that is not suspicious for carcinoma and is associated with BPH, use 600.1, Ferragamo says.
 
It's easy to see how a coder could make the mistake of using 600.1 when the notes say "prostate nodule." Any search of nodular prostate or prostate nodule in ICD-9 will yield 600.1. "That's the right code for a prostate nodule," says Laura Siniscalchi, RHIA, CPC, CCS-P, CCS, senior consultant with the Boston office of the auditing firm Deloitte and Touche. "Communication with the physician will help pinpoint what is meant."
 
Another option is to see if the patient has an elevated PSA, says Cynthia Jackson, RRA, CPC, an independent coding specialist based in Lawrenceville, Ga. "If I saw 'prostate nodule' and no other documentation, I would use 600.1."
 
Sandy Page, CPC, CCS-P, co-owner of Medical Practice Support Services of Denver, notes that it is the physician's responsibility to indicate the most accurate diagnosis and to make sure that the words in the chart will be understood. If the notes are unclear, the coder should ask the physician for clarification. "Ask the physician what he means by prostate nodule," Page says.

Ultrasound (76872)

A urologist might order a TRUS to view the prostate after detecting a nodule on rectal examination. Carriers generally consider a TRUS without biopsy a screening, which is not covered by Medicare. The biopsy must be guided ultrasonically so some carriers will pay for only one ultrasound under certain circumstances. But the urologist may perform a TRUS to see if a biopsy is warranted; this ultrasound is the hardest to be ethically reimbursed for.
 
To bill Medicare for TRUS with needle biopsy when performed by the same physician, report 76942 and 55700. When performed with a radiologist, the urologist bills 55700 and the radiologist reports 76942. If, however, the patient has a diagnostic ultrasound, which is immediately followed by needle biopsy, use 76872, 76942 and 55700. Do not bill separately for ultrasonic guidance at the time of radioactive-seed implantation.
 
Carriers often have their own rules for medical necessity, including allowable diagnosis codes and, sometimes, more requirements and limitations.

LMRP Examples

Local medical review policies (LMRPs) differ on accepted diagnoses for prostate nodules and ultrasounds:

 
  • Empire Medicare, carrier for New York City and surrounding areas, will pay for 76872, 55700 and 76942 when performed at the same session with 185 (Malignant neoplasm of prostate), 222.2 (Benign neoplasm of male genital organs; prostate), 236.5 and 790.93 (Elevated prostate specific antigen, [PSA]). Codes 600.x and 239.5 may not be used. Empire Medicare also requires that the TRUS (76872) be performed after digital rectal examination (DRE) and, sometimes, after PSA. It must be done for staging of previously diagnosed prostate cancer; for a suspicion of prostate disease based on DRE, history or PSA; volume determination prior to brachytherapy; fever in which prostatitis is the suspected cause; or suspicion of an ejaculatory duct cyst. The policy states, "Since ultrasound is unable to establish a diagnosis, it is not medically necessary when a palpable nodule is present and a diagnostic biopsy is already indicated."

     
  • Trailblazer allows 76872 for 185, 236.5, 600.0, 600.1, 600.2 (Benign localized hyperplasia of prostate), 600.3 (Cyst of prostate), 600.9 (Hyperplasia of prostate, unspecified), 601.0 (Acute prostatitis), 601.2 (Abscess of prostate), 601.3 (Prostatocystitis), 601.4 (Prostatitis in diseases classified elsewhere), 601.8 (Other specified inflammatory diseases of prostate), 601.9 (Prostatitis, unspecified), 602.9 (Unspecified disorder of prostate) and 790.93. The LMRP warns: "Transrectal ultra-sonography performed for screening purposes is a program exclusion, and an advance notification is not required. It is recommended that the provider/ physician notify the patient in advance that Medicare will not cover for a screening test and that the patient will be liable for the cost of the service. Many providers/physicians have found that advising their patient of a noncovered service is a good business practice which results in fewer problems for their staff and patients."
     
    Trailblazer allows no exceptions: "Diagnosis(es) must be present on any claim submitted, and must be coded to the highest level of specificity." Also, "The diagnosis code(s) must be representative of the patient's condition." Despite the verbiage on not using TRUS for screening, the medical-necessity list includes benign prostate diagnoses. Also, 239.5, which clinicians feel is the most appropriate diagnosis code for a prostate nodule that might require a biopsy, is not on the list. Coders should include documentation on the reason for TRUS for claims with benign diagnosis and contact the carrier when considering using 239.5.

     
  • Upstate Medicare (New York) allows 185, 222.2, 233.4 (Carcinoma in situ of breast and genitourinary system; prostate), 236.5, 606.0-606.9 (Infertility, male ) and V10.46 (Personal history of malignant neoplasm; prostate) for 76872. The LMRP warns: "By itself, echography or ultrasonography has no validity as a screening test. There will be no reimbursement without clinical indication. The fundamental premise for transrectal echography of the prostate should be to determine if a biopsy should be performed or to stage a carcinoma." On nodules, it will not cover screening of patients with benign hyperplasia unless there are also "significant clinical indicators. Since ultrasound is unable to establish a diagnosis, it is not reimbursable (i.e., not medically necessary) when a palpable nodule is present and a diagnostic biopsy is already indicated." The LMRP explains its noncoverage of TRUS for benign nodules even though 600.1 is not on its list of covered diagnoses.

     
  • HGSAdministrators, the carrier for Pennsylvania, for a TRUS, allows 185, 222.2, 233.4, 236.5, 239.5, 600.0-600.9, 601.0-601.9, 602.8 (Other specified disorders of prostrate), 602.9, 790.93 and V10.46. This policy also says it will not cover transrectal ultrasound for "screening of asymptomatic patients." But there is no extra verbiage, as there is in New York and New Jersey, limiting 76872. The policy states, "The medical record should include the patient's history, signs and symptoms, and prior pertinent laboratory studies that substantiate the medical necessity for performing transrectal echography. This information must be available to the carrier upon request."
     
    Note: When repeat biopsies are performed on a nodule of uncertain behavior, bill 55700 and 76942 only with 236.5. Repeat TRUS are not usually needed in follow- up and most likely will not be paid.

  • PSA

    PSA (84153 or 84154) is often performed to evaluate a suspicious prostatic nodule. Medicare covers screening DRE (G0102) and PSA (G0103).
     
    Two examples demonstrate carrier variation on medical necessity for PSA testing:

     
  • The Upstate (New York) Medicare division will reimburse for PSA with 185, 233.4, 236.5, 790.93 and V10.46, not 239.5 or 600.x.

     
  • HGSAdministrators allows PSA for nodules, stating in its LMRP introduction that it is "useful in assessing nodular abnormalities of the prostate." Covered diagnoses for 84153 are 185, 222.2, 233.4, 236.5, 600.0, 600.1-600.3, 600.9, 601.0-601.4, 602.0 (Calculus of prostate), 602.1 (Congestion or hemorrhage of prostate), 602.2, (Atrophy of prostate) 602.8, 602.9, 790.93 and V10.46. For 84154, it allows 790.93 only.

  • Follow Your LMRP

    Although many carriers will reimburse for a TRUS with a diagnosis of BPH or BPH-nodule, they will not pay for a screening. Physicians should know how their carriers prefer filing these claims, Jackson says: "They need to be aware of what their Medicare carrier allows."
     
    In addition to checking the current LMRP, keep track of bulletins and newsletters from carriers, which update coding information.

    Other Articles in this issue of

    Urology Coding Alert

    View All